|Articles|January 1, 1997

Managing Hypercholesterolemia and Coronary Heart Disease
Volume 3
Issue 1 Suppl

The Importance of Lipid Lowering and Other Risk Reduction Therapies

Author(s)Sidney C. Smith, Jr, MD

Download PDF: The Importance of Lipid Lowering and Other Risk Reduction Therapies

Articles in this issue

over 29 years ago

Article

MCO Decisions and Solutions

over 29 years ago

Article

Matching Risks to Interventions: When to Treat, How to Treat

over 29 years ago

Article

CME Quiz

over 29 years ago

Article

Bibliography

over 29 years ago

Article

Participants

over 29 years ago

Article

Goals and Objectives

over 29 years ago

Article

Introduction

over 29 years ago

Article

Clinical Study Outcomes and the Benefits of Treating Hypercholesterolemia

over 29 years ago

Article

Goals for Patient Treatment

over 29 years ago

Article

Pharmacoeconomics: The Cost Effectiveness of Lipid Management

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

The Importance of Lipid Lowering and Other Risk Reduction Therapies

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

The Importance of Lipid Lowering and Other Risk Reduction Therapies

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention